Inhibition of monoamine oxidase by phthalide analogues

被引:25
作者
Strydom, Belinda [1 ]
Bergh, Jacobus J. [1 ]
Petzer, Jacobus P. [1 ]
机构
[1] North West Univ, Sch Pharm, ZA-2520 Potchefstroom, South Africa
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
Phthalide; 2-Benzofuran-1(3H)-one; Monoamine oxidase; MAO-B; Reversible inhibition; Structure-activity relationship; PARKINSONS-DISEASE; BRAIN; DERIVATIVES;
D O I
10.1016/j.bmcl.2013.01.003
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues. Phthalide is structurally related to isatin and phthalimide and it is demonstrated here that substitution at C6 of the phthalide moiety yields compounds endowed with high binding affinities to both human MAO isoforms. Among the nineteen homologues evaluated, the lowest IC50 values recorded for the inhibition of MAO-A and -B were 0.096 and 0.0014 mu M, respectively. In most instances, C6-substituted phthalides exhibit MAO-B specific inhibition. Among a series of 6-benzyloxyphthalides bearing substituents on the para position of the phenyl ring the general order of potency was CF3 > I > Br > Cl > F > CH3 > H. The results also show that the binding modes of representative phthalides are reversible and competitive at both MAO isoforms. Based on these data, C6-substituted phthalides may serve as leads for the development of therapies for neuro-degenerative disorders such as Parkinson's disease. (c) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1269 / 1273
页数:5
相关论文
共 27 条
  • [1] Moclobemide: Therapeutic use and clinical studies
    Bonnet, U
    [J]. CNS DRUG REVIEWS, 2003, 9 (01): : 97 - 140
  • [2] Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase
    Booysen, Hermanus P.
    Moraal, Christina
    Terre'Blanche, Gisella
    Petzer, Anel
    Bergh, Jacobus J.
    Petzer, Jacobus P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (24) : 7507 - 7518
  • [3] CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
  • [4] Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys
    DiMonte, DA
    DeLanney, LE
    Irwin, I
    Royland, JE
    Chan, P
    Jakowec, MW
    Langston, JW
    [J]. BRAIN RESEARCH, 1996, 738 (01) : 53 - 59
  • [5] Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
    Fernandez, Hubert H.
    Chen, Jack J.
    [J]. PHARMACOTHERAPY, 2007, 27 (12): : 174S - 185S
  • [6] Finberg JPM, 1998, J NEURAL TRANSM-SUPP, P279
  • [7] Age-related increases in brain monoamine oxidase B in living healthy human subjects
    Fowler, JS
    Volkow, ND
    Wang, GJ
    Logan, J
    Pappas, N
    Shea, C
    Macgregor, R
    [J]. NEUROBIOLOGY OF AGING, 1997, 18 (04) : 431 - 435
  • [8] Inhibition of monoamine oxidases by functionalized coumarin derivatives: Biological activities, QSARs, and 3D-QSARs
    Gnerre, C
    Catto, M
    Leonetti, F
    Weber, P
    Carrupt, PA
    Altomare, C
    Carotti, A
    Testa, B
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (25) : 4747 - 4758
  • [9] MONOAMINE OXIDASES OF THE HUMAN-BRAIN AND LIVER
    KALARIA, RN
    MITCHELL, MJ
    HARIK, SI
    [J]. BRAIN, 1988, 111 : 1441 - 1451
  • [10] MONOAMINE-OXIDASE ACTIVITY IN BRAIN MICROVESSELS DETERMINED USING NATURAL AND ARTIFICIAL SUBSTRATES - RELEVANCE TO THE BLOOD-BRAIN-BARRIER
    LASBENNES, F
    SERCOMBE, R
    SEYLAZ, J
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1983, 3 (04) : 521 - 528